Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
16 results
- D1.532 - Phenotypic and Functional Comparison of LAD2, HMC-1.2, and Primary Human Mast Cells
- D1.529 - Evaluating the Disease-Modifying Potential of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis: An Update on the Pivotal HARBOR Study
- D1.530 - Patient Experience of Most Burdensome Nonadvanced Systemic Mastocytosis Symptoms From the Pivotal Summit Trial of Bezuclastinib
- D1.531 - Avapritinib in Indolent Systemic Mastocytosis: Real-world Data from a Greek Case Series
- D1.533 - Systemic mastocytosis despite normal baseline tryptase: a diagnostic pitfall in recurrent life-threatening anaphylaxis
D3.430 - The effect of biological treatment of atopic dermatitis in children
D3.431 - Dupilumab therapy of patients with chronic rhinosinusitis with nasal polyps: long-term observational study
D3.432 - Severe chronic rhinosinusitis - diagnostic and therapeutic challenges, personalized approach and place of biological treatment: a clinical case
D3.433 - An effect on lipid profile of biologic therapy independent from weight variation
D3.434 - Effectiveness of Biologic Therapies in Adults With Chronic Rhinosinusitis With Nasal Polyps: Real-World Data
D3.435 - “Looking Twice in Atopic Dermatitis Therapy: Pruritus Is Not Always the Same, and Eczema Is Not Always Atopic Dermatitis”
- D3.545 - Natural Killer and Dendritic Cells Leverage Synergistic Interactions to Enhance Treatment of Non-Small Cell Lung Cancer
- D3.544 - Allergic biomarkers and clinical outcomes in lung cancer patients treated with immune checkpoint inhibitors: a pilot study
- D3.546 - AllergoOncology: Basophil number and subpopulation proportions may offer potential as predictive biomarkers in non-small cell lung cancer
- D3.547 - Clinical Outcomes and Safety of Drug Desensitization in Chemotherapy-Induced Hypersensitivity
- D3.548 - Refractory and persistent pruritus in an atopic patient: A red flag for underlying malignancy?
Download the app
The congress at your fingertips
Available on
Download